GnRH for Luteal Support in IVF/ICSI/FET Cycles

Part of paid clinical trials in Hasbrouck Heights, New Jersey.

Sponsor
University Reproductive Associates
Study ID
NCT02357654
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

  • Infertility

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 40 Years
Healthy Volunteers
Not accepted

Interventions

  • GnRH — DRUG
    single shot of GnRH agonist
  • placebo — DRUG
    placebo

Study Details

During IVF cycles an embryo is generally placed into the uterine cavity between 3 and 5 days after fertilization. For a successful pregnancy to take place, that embryo must then implant in the properly primed and staged endometrium, which subsequently must continue to develop to accommodate the growing and maturing embryo and then fetus. This process is normally regulated by hormonal interactions between the fetal, endometrial and luteal tissue. It has been found that after IVF additional support for the endometrium with progesterone improves implantation and subsequent live birth rates in IVF cycle . Recent data has shown that additional supplementation with a single administration of a GnRH agonist around the time the time of embryo transfer may further enhance these rates .

Key Dates

Start date
Nov 30, 2015
Status verified
Jul 2025
Primary completion
Jul 31, 2026
Completion
Jul 31, 2026

Study Design

Enrollment
350 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: GnRH agonist
  • Placebo Comparator: Placebo

Primary Outcome Measure

Live birth per transfer [ Time Frame: 9 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University Reproductive AssociatesHasbrouck HeightsNew Jersey07604
Peter G. McGovern, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Hasbrouck Heights, NJ

By research site
University Reproductive Associates· Hasbrouck Heights, NJ

Related Studies